Huiyi Li

Dr. Huiyi Li

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2022 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
ZXZi-Xin Xu
Zi-Xin Xu
JLJing-Ze Li
Jing-Ze Li
QLQin Li
Qin Li
MXMing-Yi Xu
Ming-Yi Xu
HLHuiyi Li
Huiyi Li

7 December 2017 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
HLHuiyi Li
Huiyi Li
XLXiao Liang
Xiao Liang
QCQi Chen
Qi Chen
WZWei Zhang
Wei Zhang
HLHong Lu
Hong Lu
Background: In recent years, success rates of empirical H. pylori therapies have fallen in many countries. Although antibiotic resistance and poor adherence are described as the main factors for treatment failure, in China, iatrogenic factors also play an important role. Objective: To investigate why patients experienced multiple failures, we performed a retrospective, single center study using questionnaires to identify causes of treatment failure other than antibiotic resistance. Methods: This study was conducted from January 2016 to July 2017 in a general hospital. Patients with at least two H. pylori treatment failures who completed the questionnaire were entered. The survey covered characteristics of the study population, regimens used, and adherence to therapy. Results: Two hundred and ninety three patients were included in the final analysis. The top three most antibiotic combinations as the first-line treatment were a PPI plus clarithromycin–metronidazole (24.6%, 72/293), clarithromycin–levofloxacin (23.5%, 69/293) and clarithromycin–amoxicillin (21.5%, 63/293). Clarithromycin-containing regimens were repeatedly used in 178 patients (60.8%) and levofloxacin-containing regimens repeatedly in 88 patients (30.0%). Fifty patients (17.1%) had poor adherence per treatment history and 32 (10.9%) stopped treatment because of nonmedical reasons. Conclusions: In order to increase the success of H. pylori eradication therapy, the effect of prior therapies needs to be given more consideration. Patient education to enhance adherence also needs to be improved.

29 March 2021 in Helicobacter
Verified
Journal Article
Closed access
PDF file
YHYu Huang
Yu Huang
HLHuiyi Li
Huiyi Li
XLXiaohua Long
Xiaohua Long
XLXiao Liang
Xiao Liang
HLHong Lu
Hong Lu

6 February 2023 in Inflammation Research
Verified
Journal Article
Closed access
PDF file
HLHuiyi Li
Huiyi Li
SFSeng-Wang Fu
Seng-Wang Fu
JWJuncheng Wu
Juncheng Wu
ZLZhenghong Li
Zhenghong Li
MXMing-Yi Xu
Ming-Yi Xu

17 June 2021 in Frontiers in Materials
Verified
Journal Article
Open access
BLBingyun Lu
Bingyun Lu
LPLijun Peng
Lijun Peng
SLShenggen Luo
Shenggen Luo
JZJing’e Zhou
Jing’e Zhou
NXNan Xu
Nan Xu
QLQinghua Li
Qinghua Li
Background: The short half-life of TRAIL (tumor necrosis factor–related apoptosis-inducing ligand) greatly limits its clinical application. This study was aimed to improve its potency on liver fibrosis through PEG (polyethylene glycol) modification prolonging the half-life of TRAIL.Methods: PEG, TRAIL, and the chemically synthesized complex PEG-TRAIL were used to treat 3T3 and LX-2 cells and liver fibrotic mice. In vitro, cell viability, apoptosis, and fibrosis were investigated using CCK-8 (cell counting kit-8) assay, flow cytometry, and Western blotting, respectively. In vivo, Sirius red staining, immunohistochemistry, and α-SMA (α-smooth muscle actin)/TUNEL (terminal deoxynucleotidyl transferase dUTP [2'-deoxyuridine 5'-triphosphate] nick end labeling) double-labeling immunofluorescence (IF) were performed after various treatments for liver fibrotic mice. The fibrotic liver was subjected to DR4 (death receptor 4)/TRAIL double-labeling IF to assess the retention of TRAIL enhanced by PEGylation.Results: The cells treated with PEG-TRAIL showed lower cell viability, higher apoptosis level, and stronger anti-fibrotic effect compared with PEG or TRAIL treatment. In vivo, PEGylated TRAIL exhibited a longer circulation than TRAIL did. Compared with TRAIL treatment, PEG-TRAIL caused a significant reduction of α-SMA and a markedly increase of apoptotic aHSCs. PEGylation is more likely to prolong the retention of TRAIL in circulation and enhance the possibility to target aHSCs and DR4-positive (DR4+) cells in the liver.Conclusion: PEG-TRAIL presents better anti-fibrotic and proapoptotic effects, for which, the prolonged circulation half-life in vivo may account. The PEG-TRAIL may serve as a new clinical therapeutic for liver fibrosis in the future.